The data could revive the Alzheimer’s drug market to return its focus to amyloid plaques. Over the past few years, pharmaceutical companies have been wary to invest in treatments that exclusively factor amyloid plaque buildup after multiple trials failed to show promise.
Aduhelm, Biogen’s Alzheimer’s drug that spurred controversy after an FDA panel raised concerns about its efficacy, was designed to target amyloid plaque.
The narrative seems to be shifting again after Biogen’s shares rose 36 percent after the most recent trial data was released, according to the Journal.
